The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors

New direct acting antivirals (DAAs) such as daclatasvir (DCV; BMS-790052), which target NS5A function with picomolar potency, are showing promise in clinical trials. The exact nature of how these compounds have an inhibitory effect on HCV is unknown; however, major resistance mutations appear in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lambert, Sebastian M, Langley, David R, Garnett, James A, Angell, Richard, Hedgethorne, Katy, Meanwell, Nicholas A, Matthews, Steve J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093949/
https://www.ncbi.nlm.nih.gov/pubmed/24639329
http://dx.doi.org/10.1002/pro.2456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093949/
https://www.ncbi.nlm.nih.gov/pubmed/24639329
http://dx.doi.org/10.1002/pro.2456

Ejemplares similares